Abstract

To quantitate key parameters of the platelet-rich plasma (PRP) product from five commercial canine PRP systems in healthy, adult canines. A prospective study was performed from January 2013 to April 2014. Five commercial systems were analyzed using 10 healthy dogs per system.(-) Blood was obtained according to the manufacturer's protocol for each system. The mean baseline whole blood platelet, RBC, WBC, neutrophil, monocyte, and lymphocyte concentrations were determined for each PRP system. All blood samples were processed according to the manufacturer's protocols. The mean PRP product platelet, RBC, WBC, neutrophil, monocyte, and lymphocyte concentrations were determined for each PRP system. These values were then compared to the mean baseline values. Comparisons of mean whole blood and mean PRP product parameters were calculated using a paired t-test with significance established at p = 0.05. Platelet concentration was significantly increased for System 1 (p = 0.0088) and System 3 (p < 0.0001), and was significantly decreased for System 2 (p < 0.0001). All five systems significantly decreased the red blood cell concentration (p < 0.0001 for each system comparison). Neutrophil concentration was significantly decreased for System 2, System 3, and System 4 (p < 0.0001 for each system comparison). Neutrophil concentration was significantly increased for System 5 (p = 0.0089). The systems with the highest platelet yield were System 1 and System 3. System 3 increased platelet concentration while significantly reducing the RBC and neutrophil concentrations. Further study is indicated to assess the efficacy of PRP therapy in canines, the efficacy of canine PRP systems, and the clinical applications for PRP therapy in dogs.

Highlights

  • Platelet-rich plasma (PRP) is an autogenous fluid concentrate composed primarily of platelets and growth factors

  • The mean baseline whole blood platelet, red blood cell (RBC), white blood cell (WBC), neutrophil, monocyte, and lymphocyte concentrations were determined for each PRP system

  • The mean PRP product platelet, RBC, WBC, neutrophil, monocyte, and lymphocyte concentrations were determined for each PRP system

Read more

Summary

Introduction

Platelet-rich plasma (PRP) is an autogenous fluid concentrate composed primarily of platelets and growth factors. Recent studies have shown PRP to be efficacious in managing many different orthopedic conditions, including osteoarthritis and soft tissue injuries [3, 4, 7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31]. PRP has been used in conjunction with stem cell therapy to aid in cartilage, bone, and soft tissue healing

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.